JY, S., CJ, C., C, A., J, D., MD, O., R, D., . . . group, V. (. s. (2021). Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged =50 years: A randomized phase III trial (PNEU-PATH).
Citación estilo ChicagoJY, Song, et al. Safety, Tolerability, and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Followed By Sequential PPSV23 Vaccination in Healthy Adults Aged =50 Years: A Randomized Phase III Trial (PNEU-PATH). 2021.
Cita MLAJY, Song, et al. Safety, Tolerability, and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Followed By Sequential PPSV23 Vaccination in Healthy Adults Aged =50 Years: A Randomized Phase III Trial (PNEU-PATH). 2021.